18 research outputs found
Should patients with severely impaired left ventricular function following myocardial infarction receive an implantable defibrillator?
Too much or not enough? A comment on discrepancies in published estimates of opioid use in Australia
Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Response to Michael Wonder’s comments on the article ‘Assessment of the therapeutic value of new medicines marketed in Australia’
All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study
Drug use evaluation of ipratropium bromide at two tertiary referral hospitals in Brisbane.
Objective: To assess the appropriateness of ipratropium bromide prescribing in two tertiary referral hospitals. Method: Criteria for optimal use were developed based on current literature and modified after consultation with respiratory physicians and clinical pharmacists. A prospective review of prescribing was performed over a 2-month period to assess conformity to these criteria. Results: Information was collected from 84 patients; 5% were receiving inhalers and 96% nebuliser therapy (one patient used both). 77% of patients (n = 65) had a principal diagnosis of chronic obstructive pulmonary disease, 14% (n = 12) asthma and 8% (n = 7) had neither diagnosis. 75% of patients were using ipratropium outside the guidelines. The major areas where the guidelines were not met were a lack of therapeutic justification, use of inappropriate doses, and use of an inappropriate delivery device. Feedback and educational interventions were designed and delivered based on the data obtained. Conclusions: There was widespread use of ipratropium outside the developed guidelines. Interventions in specific areas could lead to significant improvements in the use of this high cost dru
